Press releases

March 21, 2018
Kyn Therapeutics Appoints Chairman and Scientific Advisory Board Member

December 14, 2017
Kyn Therapeutics Announces $49 Million Series A Capital Available to Develop Cancer Therapy Candidates with Novel Approaches to Major Immunometabolism Pathways

view all Tweets


Did you know that the tumor microenvironment (TME) is an incredibly important space for cancer drug development? Re… http://HK98fRBVlT

Great recent high-level review in @biocentury of the state-of-play in immuno-metabolism at:… http://5AsCOE985q

We're proud to support and showcase work by local artists Estelle Disch and Nancy Beams, members of… http://dlS09K71Li

Kyn advisor and immunotherapy expert Dr. Pawel Kalinski speaks today on COX2-PGE2-mediated immunosuppression in tum… http://LVi3kIWGZY

Media contact

Tom Donovan
Ten Bridge Communications


Sign up to get up-to-date news about Kyn Therapeutics.

Contact us

Find us

Kyn Therapeutics
1030 Massachusetts Avenue
Suite 400
Cambridge, MA 02138

Call us


Email us

Friend us